ACUMEN PHARMACEUTICALS, INC.
427 Park St.
Charlottesville, Virginia 22902
July 6, 2022
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Daniel Crawford | |
| Re: | Acumen Pharmaceuticals, Inc. | |
| Registration Statement on Form S-3 (File No. 333-266004) | ||
| Request for Acceleration of Effective Date | ||
Mr. Crawford:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-266004) (the “Registration Statement”) to become effective on July 8, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Sarah Sellers of Cooley LLP, counsel to the Registrant, at (212) 479-6370, or in her absence, Katherine Denby at (202) 776-2070.
[Signature page follows]
| Very truly yours, | ||
| Acumen Pharmaceuticals, Inc. | ||
| By: | /s/ William Matthew Zuga | |
| William Matthew Zuga | ||
| Chief Financial Officer | ||
| cc: | Daniel O’Connell, Acumen Pharmaceuticals, Inc. |
Sarah Sellers, Cooley LLP
Katherine Denby, Cooley LLP
Signature Page to Company Acceleration Request – S-3
